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ABSTRACT  39 
 40 
Equol (a bacterial metabolite of the soy isoflavone daidzein) is produced by 30-50% of humans 41 
and may be associated with health outcomes. We hypothesized that plasma equol would be 42 
inversely associated with risks of fibrocystic breast conditions (FBC) and breast cancer (BC). 43 
Plasma from women in a breast self-examination trial in Shanghai with BC (n=269) or FBC 44 
(n=443), and age-matched controls (n=1027) was analyzed for isoflavones. Equol was grouped 45 
into categories (<20, 20-<45, and ≥45 nmol/L) and, among women with daidzein ≥20 nmol/L, 46 
the log10 equol:daidzein ratio was grouped into tertiles. Where available, non-cancerous tissue 47 
(NCT) adjacent to the carcinomas from women with BC were classified as non-proliferative or 48 
proliferative (n=130 and 172, respectively). The lesions from women with FBC were similarly 49 
classified (n=99 and 92, respectively). Odds ratios (OR) and 95% confidence intervals (CI) were 50 
calculated across equol categories and tertiles of log10 equol:daidzein ratio. Equol categories 51 
were not associated with FBC or BC (p>0.05). For log10 equol:daidzein, compared to controls 52 
there were positive associations in the mid tertile for proliferative FBC (OR 2.06, 95% CI 1.08-53 
3.93), BC with proliferative NCT (OR 2.95, 95% CI 1.37-6.35), and all BC regardless of 54 
histology (OR 2.37, 95% CI 1.43-3.95). However, trends in ORs with increasing plasma equol 55 
values or equol:daidzein ratios were not observed (p>0.05). The results of this study do not 56 
provide evidence that equol plays a role in the etiology of these breast conditions. However, 57 
further work is needed to confirm or refute this conclusion.    58 
 59 
KEYWORDS: breast cancer; daidzein; equol; fibrocystic changes in the breast; isoflavone; 60 
nested case-control study; women61 
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1. INTRODUCTION  62 
 63 
Soy contains the isoflavones daidzein and genistein [1, 2], and is consumed in high amounts in 64 
Asian populations [3-5] and in low amounts by Western populations [6]. Isoflavones are 65 
structurally similar to mammalian estrogens [7] and research has focused primarily on their 66 
effects on hormone-related conditions, including risk of breast cancer. However, associations 67 
between soy or isoflavone consumption and breast cancer risk have been inconsistently observed 68 
[8]. Reasons for such differences are unclear but one reason may be due to inter-individual 69 
differences in isoflavone metabolism.  70 
 71 
Gut microbiota are involved in the metabolism of daidzein to equol [9] and, following soy 72 
consumption, approximately 30-50% of individuals produce equol (discussed in [10]). In vitro, 73 
equol was shown to have greater biological activity than daidzein, and to have a higher effective 74 
free fraction in serum than genistein and 17β-estradiol (discussed in [10]). Thus, it has been 75 
suggested that individuals ability to produce equol be considered in studies assessing soy intake 76 
and health [11].  77 
 78 
Two small studies in Asian and Asian-American populations have shown, albeit non-79 
significantly, lower excretion of equol or a lower proportion of equol-producers than non-80 
producers in breast cancer cases than controls [12, 13], suggesting decreased risk of breast cancer 81 
in equol-producers. Similar findings were shown in Western populations [14-16], although one 82 
study initially reported an increased risk [17] that attenuated with a larger sample size [18]. 83 
Among Chinese immigrant women in the US, mammographic breast density (a marker of risk 84 
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for breast cancer) was lower (representing lower risk) in equol-producers than non-producers, 85 
and when stratified on equol-producer status, isoflavone intake was inversely associated with 86 
breast density among equol-producers but not non-producers [19]. Further, in a cross-sectional 87 
study of predominantly White postmenopausal women in the US, there was a suggestion of a 88 
favorable interaction between soy intake and equol-producer status on breast density [20].  89 
 90 
Proliferative fibrocystic breast conditions (FBC) have been associated with increased risk of 91 
breast cancer [21, 22]. We showed previously that plasma genistein and daidzein concentrations 92 
were inversely associated with risk of breast cancer and benign FBC among women in Shanghai, 93 
China [23]. Associations between equol and these breast conditions remains largely unknown 94 
and was the focus of this study. We hypothesized that, in this same population, plasma equol 95 
would also be inversely associated with risk of breast cancer and benign FBC. Our specific 96 
objectives were to 1) examine associations between equol and risk of breast cancer and benign 97 
FBC, and 2) examine these associations stratified by proliferative status of the lesions from 98 
women with FBC and of the adjacent non-cancerous tissue of breast cancer cases. Another 99 
objective was to confirm whether our previously reported inverse associations between plasma 100 
genistein and daidzein concentrations and risk of breast cancer and benign FBC would remain 101 
when assessed in a larger sample. We tested these objectives using a case-control study design 102 
that was nested within a large trial of breast self-examination [24].  103 
 104 
105 
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2. METHODS AND MATERIALS  106 
 107 
2.1 Study Population  108 
 109 
266,064 women (ages 30-64 years) who were current or retired employees of the Shanghai 110 
Textile Industrial Bureau (STIB) were enrolled in the breast self-examination (BSE) trial 111 
between October 1989 and October 1991 and followed for the development of benign and 112 
malignant breast disease through July 31, 2000. Briefly, participants in this study were from two 113 
nested case-control studies of benign and malignant breast conditions that were conducted 114 
sequentially between September 1995 through August 1997 and between September 1997 and 115 
July 2000. The overall recruitment of cases and controls has been described previously [23, 25].    116 
 117 
The Institutional Review Board of the Fred Hutchinson Cancer Research Center and the Station 118 
for Prevention and Treatment of Cancer in the STIB approved the study, in accordance with the 119 
assurances of the Office for Human Research Protection of the US Department of Health and 120 
Human Services. Informed consent was obtained prior to interview and blood draw. 121 
 122 
2.1.1 Case selection 123 
 124 
Case selection has been described in detail elsewhere [23, 25]. New cases of breast cancer (BC) 125 
and benign breast disease were identified through review of factory medical clinic records and 126 
visits to STIB hospitals. As described previously [25] 622 women with histologically confirmed 127 
fibrocystic breast conditions (FBC) and 432 with BC were identified. For breast cancer cases 128 
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with adequate non-cancerous tissue (NCT) (at least 5 scanning power fields) from their biopsy, 129 
the NCT was classified by one pathologist (ML) according to the scheme developed by Stalsberg 130 
[26] as: nonproliferative (mild or no ductal hyperplasia and mild or no sclerosing adenosis), 131 
proliferative without atypia (moderate or florid ductal hyperplasia or moderate or predominant 132 
sclerosing adenosis and no atypia), or atypia (atypical ductal hyperplasia, atypical lobular 133 
hyperplasia or moderate apocrine atypia). The lesions from women with FBC (and no breast 134 
cancer) were similarly classified if adequate tissue was available. 135 
 136 
As detailed elsewhere [27], in-person interviews were conducted primarily before histologic 137 
diagnosis. Data collected during the interviews included demographics, medical history, and 138 
known and suspected breast cancer risk factors (see [27] for more information). In our previous 139 
study [23], women were excluded from analyses if blood was drawn >30 days prior to diagnosis 140 
or >30 days from date of interview. For the present study, the time frame was expanded a priori 141 
to include samples taken up to 90 days prior to diagnosis, given that most individuals maintain 142 
producer/non-producer phenotypes over time and assignment of phenotypes is unlikely to be 143 
influenced by timing of sampling. This resulted in the inclusion of two additional samples (taken 144 
at 40 and 47 days prior to diagnosis). Samples drawn within 14 days after diagnosis were 145 
included. Interviews were completed for 551 women with FBC (89%), and 443 of these (81%) 146 
had plasma that was analyzed for equol (49 samples had been drawn after diagnosis). 302 (68%) 147 
of these had histologic classifications as described. Interviews were completed for 378 (88%) 148 
women with BC, and equol was measured in plasma from 269 (71%) women (23 samples had 149 
been drawn after diagnosis). Of these, 191 (71%) had sufficient NCT for histologic classification.  150 
 151 
8 
 
2.1.2 Control selection 152 
 153 
Control selection has been described in detail elsewhere [23, 25]. Controls were selected from 154 
unaffected women in the BSE cohort and were frequency-matched to cases on age. Between 155 
1995 and 1997 two controls per benign or malignant case (matched to case on age and menstrual 156 
status) were recruited for a concurrent study of cell proliferation and were interviewed in their 157 
home or factory (see [23, 25] for more detail). 367 of our controls were recruited in this way. For 158 
cases enrolled between 1997 and 2000, controls were frequency matched by 5-year age group 159 
and hospital affiliation of their factory in a 1:1 case-control ratio to the largest benign or 160 
malignant case group in each age stratum. Interviews were completed in their homes or factories 161 
for 704 (82%) of the 862 controls (see [23, 25] for more detail). One control whose calculated 162 
daily energy intake was >4000 kcal was excluded. Of the 1070 eligible controls, 1027 had a 163 
blood sample drawn at interview for analysis.  164 
 165 
2.2 Measurement of plasma isoflavones  166 
 167 
Plasma was frozen and stored at -70˚C until assayed for equol using Labmaster time-resolved 168 
fluoroimmunoassay (TR-FIA) kits (Turku, Finland). This method was used because it allowed 169 
the inclusion of participants with small plasma volumes and provided for improved sensitivity 170 
over other methods. Batches had similar distributions of cases and controls. Plasma (200 l) was 171 
incubated overnight at 37oC with 0.2 U/ml β-glucuronidase from E. Coli and 15 U/ml sulfatase 172 
(Sigma-Aldrich Co., St. Louis, MO) in 200 l 0.1 M acetate buffer pH 5. Hydrolyzed samples 173 
were extracted twice, each with 1.5 ml ether. Ether fractions were dried under a stream of 174 
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nitrogen in a 37oC water bath, and the residue reconstituted in assay buffer. Samples were 175 
vortexed, left for approximately 30 minutes, vortexed again and then used in the TR-FIA. 176 
Fluorescence was measured on the Wallac Victor 2 model 1420 spectrofluorometer (Turku, 177 
Finland). Data were analyzed using GraphPad Prism software (GraphPad Software Inc., San 178 
Diego, CA). Samples with concentrations greater than the highest standard were assayed using a 179 
new plasma aliquot, but the sample was diluted in assay buffer after reconstitution. We used an 180 
estimated extraction recovery of 80% as per the package insert, and adjusted concentrations 181 
accordingly. The inter-assay CV was 14.0%, and the limit of quantification (LOQ) was 0.66 182 
nmol/L. Concentrations below this were reported as 0.33 nmol/L (i.e., half the LOQ), to allow 183 
calculation of ratios. 184 
 185 
Samples from most women had been analyzed for daidzein and genistein initially by liquid 186 
chromatography-coularray method (LC-coularray; 32% of samples) and then by liquid 187 
chromatography-mass spectrometry (LC-MS; 68% of samples); see [28] for further details on 188 
these methods. As described previously [28], the analysis method was changed from LC-189 
coularray to LC-MS because increased instrument availability at the time meant that LC-MS 190 
could be used, which improved assay efficiency and precision of the measurements. For 217 191 
samples that had not already been analyzed, Labmaster TR-FIA kits (Turku, Finland) were used 192 
to measure daidzein and genistein (64 samples for both daidzein and genistein; 49 for genistein 193 
only; and 104 for daidzein only) because samples with small volumes could be measured with 194 
improved sensitivity. Procedures were as described for equol. Daidzein concentrations <0.5 195 
nmol/L were considered below LOQ and assigned the midpoint of 0.25 nmol/L. Genistein 196 
concentrations <1.0 nmol/L were considered below LOQ and assigned the midpoint of 0.5 197 
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nmol/L. Inter-assay CVs were 9.1% for daidzein and 5.0% for genistein.  198 
 199 
2.3 Statistical Analyses  200 
 201 
The women had not received a soy challenge prior to blood sampling so a modified version of 202 
the Setchell and Cole method [29] was applied to evaluate equol production in relation to risk of 203 
FBC and BC. Setchell and Cole showed that serum equol >20 nmol/L distinguished equol 204 
producers from non-producers, and the lowest serum daidzein concentration (following soy 205 
exposure) was 16 nmol/L. Thus, we used two approaches to characterize equol exposure. First, 206 
we grouped plasma equol into three categories (<20, 20-<45, and ≥45 nmol/L). Second, we 207 
restricted analyses to women with plasma daidzein ≥20 nmol/L, calculated the ratio of equol to 208 
daidzein (to allow for variation in soy intakes and pharmacokinetics/bioavailability), and log10 209 
transformed the result, as per Setchell and Cole [29]. This yielded no clear separation of equol 210 
producers from non-producers (data not shown), so we categorized the log10 equol:daidzein ratio 211 
into tertiles according to distributions among controls. Because we restricted these analyses to 212 
women with plasma daidzein ≥20 nmol/L, additional categories (e.g., quintiles) would result in 213 
very small numbers of cases per group. To enable comparisons with previous analyses [23], we 214 
categorized daidzein and genistein concentrations into quartiles based on distributions among 215 
controls. We used conditional logistic regression models to estimate odds ratios (OR) and 95% 216 
confidence intervals (CI), and included strata for blood draw year (1995-1996, 1997, 1998-1999, 217 
2000-2001) in all models to account for potential dietary changes prior to and during recruitment. 218 
ORs were calculated across categories of equol, log10 equol:daidzein ratio, daidzein, and 219 
genistein. ORs for the log10 equol:daidzein ratio in its continuous form were also estimated. We 220 
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computed the OR of FBC and BC by comparing each case group to the combined control group 221 
(the matching of cases and controls from the first study was not retained in the analysis). We also 222 
compared malignant and benign case groups to estimate risk of BC relative to FBC.  223 
 224 
For women with histologic data, analyses were conducted according to proliferative status of the 225 
NCT. Proliferative conditions with and without atypia were combined because the number of 226 
women with atypia was small. Age (5-year categories), plasma genistein, and analysis method 227 
for genistein were included in multiple logistic models for equol. Logistic models for log10 228 
equol:daidzein were adjusted for age and plasma daidzein analysis method. We evaluated 229 
possible confounding effects of multiple factors, including age at first birth, number of live births, 230 
total duration of lactation, years of oral contraceptive use, age at first menstrual period, 231 
menopausal status, prior breast lump, times breast self-examination performed per year, body 232 
mass index, and education as per our previous analysis [27]. None changed the results 233 
appreciably (<10% change in the OR of the primary predictor variable) when added individually, 234 
and were not included in final models. Tests for trend were performed by entering categorical 235 
variables as continuous variables into regression models. All analyses were based on two-tailed 236 
probability using SAS version 9.1 (SAS Institute Inc., Cary, NC). 237 
 238 
239 
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3. RESULTS 240 
 241 
Characteristics of BC cases, women with FBC, and controls were similar to those reported in our 242 
previous studies of breast conditions in this population (Table 1) [23, 27, 30, 31].  243 
 244 
Geometric mean plasma equol concentration among controls, women with FBC, and BC cases, 245 
and also by age group are shown in Table 2. Among controls, equol concentrations ranged from 246 
below the LOQ to 395 nmol/L, and 77.5% had concentrations <20 nmol/L (Figure 1). Among 247 
BC cases, equol concentrations ranged from below the LOQ to 236 (82.9% had concentrations 248 
<20 nmol/L) and among women with FBC equol concentration ranged from below the LOQ to 249 
373 nmol/L (81.7% had concentrations <20 nmol/L). 250 
 251 
We observed no associations of benign FBC, BC, or risk of BC vs. FBC in relation to categories 252 
(i.e., <20, 20-<45, and ≥45 nmol/L) of plasma equol concentration in all women or when 253 
stratified by proliferative status of the FBC or NCT (Table 3). Associations of FBC and BC in 254 
relation to tertiles of log10 equol:daidzein ratio in women with plasma daidzein concentrations 255 
≥20 nmol/L are shown in Table 4. Proliferative FBC, BC with proliferative NCT (including 256 
atypia), and all BC combined (i.e., all women with and without histological classification) were 257 
positively associated with the second tertile of log10 equol:daidzein ratio, but trends across 258 
tertiles were not observed. Furthermore, no linear trends were observed when considering the 259 
ratio as a continuous variable. Findings did not change substantially when restricting analyses to 260 
people whose blood sample was drawn at or before diagnosis, although the OR for proliferative 261 
FBC for the second tertile of the log10  equol:daidzein ratio was attenuated (OR 1.80, 95% CI 262 
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0.92-3.51). Similarly, findings did not change substantially when restricting analyses to cases 263 
and controls with daidzein measured by LC-MS, although the ORs (95% CI) for FBC vs. 264 
controls for non-proliferative conditions were 0.38 (0.11-1.32) and 0.20 (0.04-1.01) for the 265 
second and third tertiles of the log10 equol:daidzein ratio, respectively (p trend 0.04), and 266 
proliferative FBC, BC with proliferative NCT, and BC combined (i.e., all women with and 267 
without histological classification) were no longer positively associated with the second tertile of 268 
the log10 equol:daidzein ratio. However, these findings were based on small numbers of cases.   269 
 270 
For risks of FBC and BC in relation to plasma daidzein and genistein, our findings were similar 271 
to those reported previously among the slightly smaller sample [23], although findings for 272 
genistein in relation to proliferative FBC were attenuated; briefly, the ORs (95% CI) for the 273 
highest quartiles (compared to lowest) of daidzein and genistein, respectively, were 0.17 (0.08-274 
0.38) and 0.30 (0.15-0.60) for non-proliferative FBC and 0.32 (0.15-0.67) and 0.55 (0.29-1.08) 275 
for proliferative FBC. The corresponding ORs (95% CI) were 0.26 (0.11-0.62) and 0.43 (0.20-276 
0.96) for BC with concurrent non-proliferative NCT and 0.27 (0.11-0.67) and 0.22 (0.08-0.57) 277 
for BC with concurrent proliferative NCT. 278 
  279 
280 
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4. DISCUSSION 281 
 282 
In this population-based case-control study, no trends in risks of either BC or FBC (with or 283 
without proliferative changes), were observed with increasing or decreasing levels of either 284 
plasma equol concentration or the log10 equol:daidzein ratio. Positive associations were seen for 285 
women in the mid tertile of the log10 equol:daidzein ratio for proliferative FBC, BC with 286 
proliferative NCT, and total BC. However, the absence of a trend across tertiles and no linear 287 
trend when considered in its continuous form suggests that these observations do not represent a 288 
biological phenomenon. We reject our hypothesis of an inverse association between plasma 289 
equol and risks of FBC and BC among women in Shanghai, China. The inverse association 290 
previously shown between plasma daidzein and genistein and risk of these breast conditions [23] 291 
remained with the larger sample size, although findings were slightly attenuated.   292 
 293 
The effects of equol on human health have been examined previously using blood and urine 294 
concentrations of equol or dichotomizing on ability to produce equol [10]. To measure equol, 295 
individuals must be exposed to sufficient daidzein prior to sampling. However, as noted by 296 
Setchell and Cole [29], there have been inconsistencies across studies in, for example, the 297 
amounts of soy/daidzein consumed and cut points for assigning equol-producer status. Although 298 
we did not see a clear demarcation between equol producers and non-producers using plasma 299 
concentrations, we accounted for this in our analyses by applying some of the criteria specified 300 
by Setchell and Cole [29]. Despite this, we did not see any consistent associations between equol 301 
production and risks of BC or FBC.  302 
 303 
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Our findings are in agreement with Virk-Baker et al. who reported no associations between 304 
equol-producer status (assessed using a soy challenge) and breast pathology, hyperplasia, or 305 
breast cancer among US women who had undergone breast biopsies following an abnormal 306 
mammogram [32]. In relation to potential modifying effects of equol production on other breast 307 
cancer risk factors, there have been suggestions of greater effects of isoflavone supplementation 308 
in equol-producers in relation to estrogen-responsive genes [33], or interactions between equol-309 
producer phenotype and soy intake in relation to mammographic density [19, 20]. However, a 310 
soy protein intervention study did not show equol-producer status as an effect modifier regarding 311 
mammographic density [34] and there was no effect of equol production on urinary estrogen 312 
metabolites in soy supplementation studies [35].  313 
 314 
It is possible that the lack of associations in this study may have been due to limited numbers of 315 
equol-producers or low circulating concentrations. Around 20% of the women had plasma equol 316 
concentrations ≥20 nmol/L which is on the lower end of reported proportions of equol-producers 317 
[10]. Furthermore, although equol concentration in our study was higher than or similar to 318 
plasma concentrations among men and women in studies of different cancer types in the US or 319 
Europe [13, 15, 36, 37], it was lower than concentrations in some studies in Japanese and Korean 320 
populations [38-40].  321 
 322 
Our study has several strengths. It is a large population-based study in women who typically 323 
consume soy foods [28], and most blood samples were drawn before diagnosis or treatment. 324 
However, blood was drawn from cases at the time of biopsy and women could have modified 325 
their diet prior to the hospital visit. Although this could potentially affect overall circulating 326 
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isoflavone concentrations, it is unlikely to affect the capacity of gut microbes to metabolize 327 
daidzein to equol. In addition, since most of the cases were asymptomatic and biopsies are 328 
considered a minor out-patient procedure, it is unlikely that the women altered their diets as a 329 
result of their condition.  Also, the women were not instructed to make any changes to their 330 
habitual activities or diet in preparation for the hospital visit. Another strength of this study is 331 
that the available tissue for histological classification was reviewed by one study pathologist.  332 
 333 
One limitation of our study is that we did not administer a soy challenge to classify women 334 
according to their equol-producing status. As such, we may have misclassified some individuals 335 
due to inadequate or inconsistent soy exposure. Since this misclassification would likely have 336 
been the same in cases and controls, this would have the effect of underestimating any true 337 
relationship, and could be an explanation for the absence of associations in this study. In a 338 
previous study of Chinese men and women consuming their usual diet, the number of equol 339 
producers more than doubled when a soy challenge was administered, suggesting that even in 340 
populations with high habitual levels of soy consumption the number of equol-producers may be 341 
underestimated [41]. Furthermore, in our study, equol was assessed at only one time point. 342 
Although equol production has been shown to be relatively stable within individuals over time in 343 
some studies [42, 43], others have suggested that around 6 to 20% of individuals vary or 344 
crossover equol phenotypes over relatively short periods of time [44, 45]. However, the evidence 345 
to date suggests there is more often a producer to non-producer shift than vice versa [42-45]. If 346 
that is the case, it may be more likely that non-producers rather than producers were 347 
misclassified. Another limitation of this study is that plasma equol concentrations reflect short-348 
term intake and may not reflect exposure at the relevant time for the development of proliferative 349 
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mammary epithelial changes, or of cancer initiation or progression. In addition, there may have 350 
been insufficient statistical power to evaluate associations, especially for analyses including 351 
strata with few cases. Also, different methods of isoflavone analysis were used and daidzein 352 
concentrations were slightly lower with LC-MS [28]. However, samples from both cases and 353 
controls were measured by LC-MS and it is unlikely that any systematic differences were 354 
introduced. Nonetheless, we adjusted for isoflavone analysis method in our statistical model, and 355 
when restricting analyses to samples measured by LC-MS, findings did not change substantially. 356 
Finally, our study was largely restricted to Han Chinese women residing in one industrial city in 357 
China, and the results may not be applicable to women of other races or to women living in 358 
different social or physical conditions.  359 
 360 
In conclusion, the results of this study do not provide evidence that equol plays a role in the 361 
etiology of FBC or breast cancer. However, future studies are needed to more fully explore the 362 
potential effects of equol production on risks of these breast conditions.   363 
364 
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Table 1. Selected characteristics of controls, women with fibrocystic breast conditions and breast cancer cases a 
 
  Controls Fibrocystic Breast Conditions   Breast Cancer Cases  
  n=1027 
Non-
proliferative 
n=130b 
Proliferative 
 
n=172b 
All 
 
n=443b  
Non-
proliferative 
NCTc n=99b 
Proliferative 
NCT 
n=92b 
All 
 
n=269b 
Age (years)                               
  ≤ 39 13 (1.3) 17 (13.1) 16 (9.3) 57 (12.9)  3 (3.0) 4  (4.3) 9 (3.3) 
  40-44 457 (44.5) 54 (41.5) 81 (47.1) 198 (44.7)  27 (27.3) 24 (26.1) 75 (27.9) 
  45-49 215 (20.9) 33 (25.4) 46 (26.7) 117 (26.4)  19 (19.2) 25 (27.2) 56 (20.8) 
  50-59 121 (11.8) 14 (10.8) 9 (5.2) 28 (6.3)  21 (21.2) 11 (12.0) 40 (14.9) 
  ≥ 60 221 (21.5) 12 (9.2) 20 (11.6) 43 (9.7)  29 (29.3) 28 (30.4) 89 (33.1) 
Number of live births                  
  None 37 (3.6) 7 (4.9) 8 (3.8) 20 (3.7)  6 (5.9) 6 (6.2) 16 (5.2) 
  1 694 (67.8) 95 (62.5) 137 (68.5) 350 (66.4)  49 (63.4) 57 (70.8) 145 (66.8) 
  2 119 (11.6) 12 (9.4) 12 (12.0) 30 (10.5)  23 (15.5) 9 (7.4) 44 (12.3) 
  ≥ 3 173 (16.9) 14 (23.2) 15 (15.8) 40 (19.3)  21 (15.2) 20 (15.7) 64 (15.7) 
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Age at first live birth (years) 
  ≤ 24 258 (26.3) 23 (26.3) 29 (25.8) 68 (25.9)  30 (24.5) 26 (24.0) 84 (25.0) 
  25-29 582 (58.9) 79 (60.2) 106 (59.9) 283 (60.5)  43 (52.9) 40 (51.3) 120 (54.2) 
  ≥ 30 146 (14.8) 19 (13.5) 29 (14.3) 68 (13.6)  18 (22.6) 20 (24.7) 47 (20.8) 
Months of breast feeding                
  Never 174 (17.7) 20 (17.1) 33 (16.8) 83 (18.1)  14 (16.8) 16 (21.4) 38 (17.3) 
  ≤ 6 203 (20.7) 30 (24.2) 50 (29.2) 118 (26.1)  20 (24.4) 16 (18.2) 50 (21.5) 
  7-12 352 (36.0) 44 (28.5) 50 (28.3) 146 (29.6)  26 (32.5) 30 (39.9) 83 (38.0) 
  13-24 110 (11.3) 13 (14.0) 12 (10.5) 31 (11.0)  18 (15.3) 6 (5.5) 33 (10.5) 
  ≥ 25 139 (14.3) 10 (16.2) 15 (15.2) 139 (14.3)  14 (11.0) 18 (15.0) 48 (12.8) 
Duration of oral contraceptive use                
  Never used 939 (91.5) 110 (83.4) 155 (88.1) 395 (87.1)  87 (86.9) 80 (87.6) 240 (89.8) 
  ≤ 1 year 34 (3.3) 10 (9.3) 8 (4.2) 26 (6.5)  8 (8.7) 7 (8.0) 16 (6.2) 
  > 1 year 53 (5.2) 10 (7.3) 9 (7.7) 21 (6.5)  4 (4.4) 5 (4.4) 13 (4.0) 
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Age at first menstrual period (years) 
  ≤ 13 163 (15.9) 28 (16.7) 25 (14.0) 84 (16.7)  24 (28.1) 15 (13.4) 53 (21.7) 
  14 200 (19.5) 29 (23.1) 44 (22.5) 101 (21.4)  16 (19.5) 17 (21.7) 53 (22.3) 
  15 204 (19.9) 26 (20.4) 35 (19.8) 96 (21.1)  24 (21.7) 20 (23.5) 62 (22.1) 
  16 213 (20.8) 22 (14.0) 32 (19.2) 73 (16.3)  17 (17.0) 15 (13.8) 44 (14.8) 
  ≥ 17 246 (24.0) 25 (25.8) 36 (24.4) 88 (24.6)  18 (13.7) 25 (27.6) 57 (19.1) 
Menopause                
  Yes 357 (34.8) 25 (32.0) 37 (34.0) 80 (32.9)  50 (36.5) 39 (32.4) 127 (33.7) 
Prior breast lumps                
  Yes 31 (3.1) 10 (6.7) 24 (13.5) 48 (9.8)  5 (6.3) 8 (8.6) 16 (7.2) 
Times breast self-examination per year                
  Never 697 (68.1) 47 (41.1) 70 (44.3) 169 (41.6)  51 (51.0) 51 (51.0) 140 (49.6) 
  1-6 135 (13.2) 21 (11.4) 26 (12.6) 73 (14.0)  17 (19.9) 18 (19.4) 55 (21.5) 
  7-12 186 (18.2) 59 (45.2) 70 (40.0) 185 (41.2)  29 (27.7) 22 (27.8) 68 (26.9) 
  ≥ 13 6 (0.6) 3 (2.3) 6 (3.1) 14 (3.2)  2 (1.5) 1 (1.9) 5 (2.0) 
 
 
                
28 
 
Education 
  Elementary school or less 193 (18.9) 11 (17.6) 14 (14.2) 35 (16.3)  30 (21.7) 20 (15.7) 79 (19.8) 
  Middle school 803 (78.2) 110 (75.5) 149 (80.0) 384 (77.9)  63 (74.6) 64 (76.5) 172 (74.7) 
  College 30 (2.9) 9 (6.9) 9 (5.8) 23 (5.7)  6 (3.7) 8 (7.8) 18 (5.5) 
Body mass index (kg/m2)                
  ≤ 20 192 (18.7) 39 (26.0) 36 (16.0) 116 (21.2)  16 (18.0) 17 (18.4) 43 (16.3) 
  21-25 603 (58.7) 72 (56.5) 101 (58.8) 253 (57.1)  61 (62.0) 50 (56.9) 158 (61.2) 
  > 25 232 (22.6) 19 (17.5) 35 (25.2) 73 (21.6)  22 (20.0) 25 (24.7) 68 (22.5) 
                
 
a Data are shown as n (%); total numbers per variable may not add up to the total number of women per column due to some missing data 
b Indirect age-adjusted percentages based on age distribution of the controls 
c NCT = non-cancerous tissue 
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Table 2. Plasma equol concentration among controls, women with fibrocystic breast conditions (FBC) and breast cancer (BC) cases by age 
group 
 Controls FBC cases BC cases 
 n Geometric mean 
(95% CI)a 
n Geometric mean 
(95% CI) a 
n Geometric mean 
(95% CI) a 
All ages combined 1027 6.87 (6.25, 7.55) 443 5.45 (4.76, 6.24) 269 5.59 (4.73, 6.59) 
  Age ≤39  13 7.83 (3.16, 19.40) 57 5.02 (3.27, 7.71) 9 2.88 (0.88, 9.44) 
  Age 40-44  457 6.81 (5.90, 7.85) 198 5.31 (4.33, 6.50) 75 6.41 (4.67, 8.79) 
  Age 45-49  215 5.79 (4.75, 7.06) 117 5.71 (4.42, 7.38) 56 4.68 (3.28, 6.67) 
  Age 50-59  121 6.39 (5.02, 8.14) 28 4.02 (2.52, 6.41) 40 4.65 (3.08, 7.02) 
  Age ≥60  221 8.53 (6.89, 10.6) 43 7.41 (4.92, 11.2) 89 6.46 (4.85, 8.59) 
a data presented as geometric mean and 95% confidence interval; plasma equol concentration in nmol/L  
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Table 3. Fibrocystic breast conditions (FBC) and breast cancer in relation to plasma equol concentrations 
 
  Number of women (%)   FBCs vs. controls   Breast cancer vs. controls   Breast cancer vs. FBCs 
  Control FBC Cancer   ORa 95% CI   ORa 95% CI   ORa 95% CI 
             
Equol (nmol/L)            
   Non-proliferative NCTb            
< 20  796 (77.5) 107 (82.3) 86 (86.9)  1.00 Ref.  1.00 Ref.  1.00 Ref. 
20 to <45  114 (11.1) 13 (10.0) 6 (6.1)  1.27 0.59-2.74  0.67 0.26-1.74  0.69 0.24-2.03 
≥45  117 (11.4)   10  (7.7) 7 (7.1)  1.25 0.54-2.90  0.93 0.36-2.40  0.80 0.26-2.49 
p trend       0.49   0.64   0.53 
             
   Proliferative NCT (including atypia)            
< 20  796 (77.5) 143 (83.1) 74 (80.4)  1.00 Ref.  1.00 Ref.  1.00 Ref. 
20 to <45  114 (11.1) 18 (10.5) 9 (9.8)  1.09 0.51-2.32  0.94 0.38-2.32  1.28 0.51-3.20 
≥45  117 (11.4) 11  (6.4) 9 (9.8)  0.70 0.28-1.74  1.88 0.75-4.70  1.73 0.59-5.06 
p trend       0.57   0.26   0.28 
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   Total            
< 20  796 (77.5) 362 (81.7) 223 (82.9)  1.00 Ref.  1.00 Ref.  1.00 Ref. 
20 to <45  114 (11.1) 48 (10.8) 27 (10.0)  1.05 0.61-1.80  1.06 0.59-1.83  0.97 0.56-1.67 
≥45  117 (11.4) 33 (7.4) 19 (7.1)  0.84 0.46-1.53  1.18 0.61-2.29  0.91 0.47-1.74 
p trend       0.64   0.61   0.76 
             
 
a Data are presented as odds ratios (ORs) and 95% confidence intervals (CIs); ORs were adjusted for age, plasma genistein (quartiles), and lab 
method for genistein analysis, and included a strata variable for blood draw year 
b NCT = non-cancerous tissue 
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Table 4. Fibrocystic breast conditions (FBC) and breast cancer in relation to log10 plasma equol:daidzein ratio among women with plasma 
daidzein concentration ≥20 nmol/L 
 
  Number of women (%)   FBCs vs. controls   
Breast cancer vs. 
controls   
Breast cancer 
vs. FBCs 
  Control FBC Cancer   ORa 95% CI   ORa 95% CI   ORa 95% CI 
             
Log10 plasma equol:daidzein ratio             
   Non-proliferative NCTb            
-3.35 to -1.43 258 (33.3) 20 (29.0) 19 (30.6)  1.00 Ref.  1.00 Ref.  1.00 Ref. 
-1.42 to -0.77 258 (33.3) 24 (34.8) 28 (45.2)  1.02 0.48-2.13  1.76 0.89-3.47  1.36 0.83-6.71 
-0.76 to 1.96 258 (33.3) 25 (36.2) 15 (24.2)  1.14 0.54-2.39  0.87 0.40-1.88  1.09 0.36-3.28 
p trend       0.37   0.48   0.40 
             
Continuous log10 plasma equol:daidzein ratio   1.21 0.79-1.84  0.91 0.60-1.37  0.78 0.42-1.46 
p-value      0.38   0.66   0.44 
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   Proliferative NCT (including atypia) 
-3.35 to -1.43 258 (33.3) 27 (26.5) 13 (20.3)  1.00 Ref.  1.00 Ref.  1.00 Ref. 
-1.42 to -0.77 258 (33.3) 48 (47.1) 35 (54.7)  2.06 1.08-3.93  2.95 1.37-6.35  1.37 0.59-3.22 
-0.76 to 1.96 258 (33.3) 27 (26.5) 16 (25.0)  1.05 0.51-2.16  1.36 0.58-3.23  1.36 0.51-3.67 
p trend       0.81   0.31   0.31 
             
Continuous log10 plasma equol:daidzein ratio   1.13 0.76-1.68  1.38 0.88-2.15  1.37 0.77-2.42 
p-value      0.56   0.16   0.28 
 
   Total            
-3.35 to -1.43 258 (33.3) 78 (27.8) 45 (25.6)  1.00 Ref.  1.00 Ref.  1.00 Ref. 
-1.42 to -0.77 258 (33.3) 115 (40.9) 82 (46.6)  1.57 0.99-2.51  2.37 1.43-3.95  1.44 0.85-2.43 
-0.76 to 1.96 258 (33.3) 88 (31.3) 49 (27.8)  1.17 0.71-1.93  1.26 0.72-2.18  1.10 0.62-1.94 
p trend       0.42   0.38   0.92 
             
Continuous log10 plasma equol:daidzein ratio   1.19 0.90-1.58  1.20 0.89-1.62  0.95 0.69-1.33 
p-value      0.23   0.24   0.78 
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a Data are presented as odds ratios (ORs) and 95% confidence intervals (CIs); ORs were adjusted for age and lab method for daidzein analysis, and 
included a strata variable for blood draw year 
b NCT = non-cancerous tissue
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Figure 1.  Frequency distribution of plasma equol concentration among control women a  
 
a n=1027 
